Blau Farmacêutica S.A. (BLAU3.SA)
BRL 12.57
(-5.42%)
BRL 12.57
(-5.42%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 533.52 Million BRL | 133.82% |
| 2022 | 228.17 Million BRL | -18.76% |
| 2021 | 280.85 Million BRL | -55.19% |
| 2020 | 626.71 Million BRL | 207.07% |
| 2019 | 204.09 Million BRL | 5.91% |
| 2018 | 192.7 Million BRL | 20444.56% |
| 2017 | 938 Thousand BRL | -97.22% |
| 2016 | 33.7 Million BRL | -4.95% |
| 2015 | 35.46 Million BRL | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q1 | 533.75 Million BRL | 0.0% |
| 2024 Q2 | 484.83 Million BRL | -10.0% |
| 2023 Q3 | 464.16 Million BRL | 152.26% |
| 2023 FY | 533.52 Million BRL | 133.82% |
| 2023 Q1 | 235.97 Million BRL | 3.42% |
| 2023 Q4 | 533.52 Million BRL | 14.94% |
| 2023 Q2 | 184 Million BRL | -22.02% |
| 2022 Q2 | 211.33 Million BRL | -21.65% |
| 2022 FY | 228.17 Million BRL | -18.76% |
| 2022 Q4 | 228.17 Million BRL | 6.62% |
| 2022 Q3 | 213.99 Million BRL | 1.26% |
| 2022 Q1 | 269.74 Million BRL | -3.96% |
| 2021 Q4 | 280.85 Million BRL | -3.9% |
| 2021 Q2 | 295.73 Million BRL | -51.96% |
| 2021 Q1 | 615.59 Million BRL | -1.77% |
| 2021 FY | 280.85 Million BRL | -55.19% |
| 2021 Q3 | 292.25 Million BRL | -1.17% |
| 2020 FY | 626.71 Million BRL | 207.07% |
| 2020 Q4 | 626.71 Million BRL | 15.99% |
| 2020 Q3 | 540.33 Million BRL | 28.17% |
| 2020 Q2 | 421.58 Million BRL | 124.44% |
| 2020 Q1 | 187.83 Million BRL | -7.96% |
| 2019 Q1 | 176.39 Million BRL | -8.47% |
| 2019 Q2 | 160.08 Million BRL | -9.24% |
| 2019 Q4 | 204.09 Million BRL | 41.93% |
| 2019 Q3 | 143.79 Million BRL | -10.18% |
| 2019 FY | 204.09 Million BRL | 5.91% |
| 2018 Q4 | 192.7 Million BRL | 0.0% |
| 2018 FY | 192.7 Million BRL | 20444.56% |
| 2017 FY | 938 Thousand BRL | -97.22% |
| 2016 FY | 33.7 Million BRL | -4.95% |
| 2015 FY | 35.46 Million BRL | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| Hypera S.A. | 7.97 Billion BRL | 93.306% |